SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,760.00    65.00 (0.97%)
Bid:
6,755.00
Ask:
6,765.00
Spread: 10.00 (0.148%)
Market Cap: £4.99b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Interim Management Statement

7 Nov 2014 07:00

RNS Number : 4096W
Spirax-Sarco Engineering PLC
07 November 2014
 



 

News Release

 

Friday 7th November 2014

INTERIM MANAGEMENT STATEMENT

Continued good performance in challenging markets

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement in respect of the period from 1st July 2014 to 6th November 2014.

 

Trading

In the four-month period ended 31st October 2014, organic sales growth was 5%. The profile of growth across our four segments has remained largely consistent with the first half. Watson-Marlow has again performed well with growth accelerating since June in emerging markets and North America, and with a continuing good contribution from Bio Pure that was acquired at the start of the year. In our steam specialties business, in Europe, Middle East and Africa ("EMEA") organic growth has continued at the same pace as in the first half year. In Asia Pacific, as expected when we last reported in August, we have started to reduce the high level of order book and expect further progress in reducing this order book over the remainder of this year in line with the traditional pattern in the fourth quarter. Finally in the Americas, sales growth in the four months to October improved due to Latin America.

 

In the four month period ended 31st October 2014, Group operating profit at constant currency was ahead of the comparable period in 2013. For the ten months to October 2014, the Group operating profit margin remained ahead on both a constant currency and reported basis, despite persistent exchange rate headwinds. If current exchange rates prevail for the remainder of the year, we now expect that sales for 2014 will be reduced by 6.3% on translation compared with full-year 2013 average exchange rates. The impact on operating profit continues to be somewhat greater, at an estimated 10% for the year, reflecting the same additional exchange transaction effects previously indicated.

 

Financial position

The Group remains highly cash generative and maintains a strong balance sheet, with the net cash balance increasing from £16 million at 31st December 2013 to £35 million at 31st October 2014, despite the £9 million outflow in respect of the acquisition of Bio Pure in January and the adverse impact of currency movements on translation of cash balances. The interim dividend of 19.5p per share (total cost £15 million) will be paid today. There has been no material change in the financial position of the Group during the period and the principal risks and uncertainties remain as set out on pages 26 and 27 of the 2013 Annual Report.

 

Outlook

Steam is widely used across a diverse range of industries and our markets generally reflect the pace of growth in Industrial Production, which our markets typically lag by a few quarters. The up-tick in global Industrial Production seen since late 2013 has begun to reverse and recent economic indicators point to lower rates of growth in both developed and emerging markets, particularly China. We remain focused on taking actions to out-perform our markets by generating our own growth through the implementation of our strategic growth initiatives and we will continue to focus on costs. Our business is resilient and we remain well placed if economic conditions deteriorate. We have a powerful direct-sales business model, with a wide geographic spread, diverse industrial end markets, a broad customer base and with a large proportion of our revenues deriving from customers' maintenance and operating spend. Our order book remains at a relatively high level, which is supportive of our expectation for sales growth in the remainder of the year and underpins the Board's confidence that we will make further progress in 2014.

 

 

 

Enquiries:

Nick Anderson, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

 

Note: References to profit are to adjusted profit that excludes the amortisation and impairment of acquisition-related intangible assets and acquisition and disposal costs, together with the tax effects of these items.

 

 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,700 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBGUGBGSL
Date   Source Headline
8th Jun 20261:24 pmRNSDirector/PDMR Shareholding
1st Jun 202610:28 amRNSChange in Major Shareholding
29th May 20262:24 pmRNSUpdate on Directorships held by Company Directors
27th May 20263:30 pmRNSDirector/PDMR Shareholding
26th May 20265:24 pmRNSDirector/PDMR Shareholding
19th May 20269:16 amRNSChange in Major Shareholding
14th May 20262:47 pmRNSExternal Directorships held by Company Directors
14th May 202610:39 amRNSDirector/PDMR Shareholding
13th May 20264:12 pmRNSResult of AGM
13th May 20267:00 amRNSTrading Update
8th May 20263:42 pmRNSChange in Major Shareholding
7th May 20269:03 amRNSDirector/PDMR Shareholding
8th Apr 20262:22 pmRNSDirector/PDMR Shareholding
8th Apr 20269:30 amRNSAnnual Report and Accounts 2025 and Notice of AGM
18th Mar 20264:53 pmRNSDirector/PDMR Shareholding
11th Mar 20261:53 pmRNSTotal Voting Rights
10th Mar 20265:01 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNS2025 Full Year Results
10th Mar 20267:00 amRNS2025 Full Year Results
9th Mar 20263:35 pmRNSDirector/PDMR Shareholding
9th Mar 20263:35 pmRNSDirector/PDMR Shareholding
10th Feb 20269:30 amRNSChange in Director Details
6th Feb 20263:47 pmRNSDirector/PDMR Shareholding
2nd Feb 20261:50 pmRNSChange in Director Details
30th Jan 20262:19 pmRNSHolding(s) in Company
6th Jan 20263:10 pmRNSDirector/PDMR Shareholding
18th Dec 20252:12 pmRNSCorrection: Block Listing Application
18th Dec 20252:12 pmRNSCorrection: Block Listing Application
18th Dec 202510:34 amRNSBlocklisting Application
9th Dec 20252:35 pmRNSDirector/PDMR Shareholding
18th Nov 20259:40 amRNSDirector/PDMR Shareholding
13th Nov 20257:00 amRNSTrading Update
7th Nov 20251:56 pmRNSDirector/PDMR Shareholding
5th Nov 20258:39 amRNSHolding(s) in Company
22nd Oct 20257:00 amRNSBoard Appointment
7th Oct 20255:08 pmRNSDirector/PDMR Shareholding
9th Sep 20257:00 amRNSDirector/PDMR Shareholding
1st Sep 20259:35 amRNSHolding(s) in Company
12th Aug 20257:00 amRNSBoard Committee Membership Update
12th Aug 20257:00 amRNS2025 Half Year Results
7th Aug 20257:00 amRNSDirector/PDMR Shareholding
24th Jul 20254:58 pmRNSDirector/PDMR Shareholding
9th Jul 20254:26 pmRNSDirector/PDMR Shareholding
13th Jun 20253:36 pmRNSDirector/PDMR Shareholding
14th May 20254:48 pmRNSResult of AGM
14th May 20257:00 amRNSTrading Update
8th May 202511:03 amRNSDirector/PDMR Shareholding
23rd Apr 20255:13 pmRNSChange in Director Details
22nd Apr 20253:52 pmRNSDirector/PDMR Shareholding
11th Apr 20255:04 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.